Peptide Supplier Qualification in China: A Lot-to-Document Evidence Checklist

Define the purchase before assessing the supplier

A search for a peptide manufacturer in China can return a synthesis laboratory, a stocking distributor or an OEM packaging business. Record which organisation makes the material, which laboratory tests it and which company invoices the shipment. These roles can be different. Your supplier file should explain the relationship instead of treating a trading address as a manufacturing site.

Set the intended research use, material identity, supplied form and documentation requirements in the enquiry. A generic catalogue entry leaves room for a quotation based on a different salt or pack format. When reviewing catalogue peptides, carry the product identifier into the RFQ and ask the supplier to confirm the specification revision that will govern the order.

For example, a quoted product code and a private-label name may differ legitimately. Put both in the enquiry and ask for their written mapping. This gives the purchasing and receiving teams a shared identifier without requiring them to infer a relationship from similar packaging.

• Legal supplier name, invoicing entity and operational role.
• Manufacturing site and any separate testing or repacking site.
• Material identifier, supplied form and agreed quantity basis.
• Named quality contact and an escalation route for discrepancies.

Build a connected lot evidence file

Ask for a sample document set before ordering, then require the issued records for the actual supplied lot. A specimen COA can show the reporting format; it cannot release a future shipment. Give each file a status such as specimen, pending or lot-specific. That small distinction prevents a sales attachment from becoming the receiving team’s acceptance document.

ICH Q7, section 11.4, describes batch identification, test limits, numerical results and authorised COA approval for APIs. It also addresses reissued certificates and the original manufacturer. Q7 concerns pharmaceutical API manufacture; the checklist here uses those document principles as a purchasing reference, not as proof that a research supplier is GMP compliant.

A useful proposed exercise is to choose one lot number and follow it across every attachment. Record where a distributor or repacker assigns a second number. Keep the original identifier and the conversion record together; a new label alone cannot explain the relationship.

Check what the laboratory result actually establishes

A high percentage beside “purity” needs a method and a reporting basis. Ask whether it represents chromatographic peak area, peptide content or another measurement. Identity evidence needs its own review. A molecular-mass result does not answer the same question as a chromatographic impurity result, and neither automatically establishes sterility.

The ICH Q2(R2) guidance issued by FDA in March 2024 treats fitness for the intended analytical purpose as the objective of validation. For procurement, ask the laboratory what its procedure measures, its relevant limitations and whether the reporting range covers the specification. Do not infer method suitability from an instrument photograph. Our COA interpretation article separates these measurements with a worked purchasing example.

When asking for attachments, specify readable report identifiers and complete result pages. If the laboratory uses a different sample code, request the controlled mapping to the manufacturing lot. This is a document request, not an instruction to alter an issued laboratory report.

Questions worth sending to the quality contact

• Which result supports identity, and which supports the impurity limit?
• Are the attached records for this sample and lot?
• Does the reported unit match the signed specification?
• Who approves a correction, and how is the earlier version withdrawn?

Agree what happens when the supplied material changes

Qualification continues after the first order. Ask the supplier to identify changes that require notice: manufacturing site, test method, salt form, specification revision, packaging configuration or a subcontracted operation. Record whether notification is required before shipment and who can approve a change on the buyer’s side. Avoid a clause that merely promises to “inform customers” without defining the affected orders.

For a private-label project, retain the approved artwork alongside the material specification. A new product name on a carton should not break the link to the manufacturing lot. Confidential supporting information can be handled under an NDA or reviewed by an agreed auditor. A refusal to disclose information is a commercial constraint to resolve; it is not evidence that an unseen record exists.

For a repeat order, send the last accepted specification revision with the enquiry and ask for an explicit confirmation or change list. That comparison is more useful than assuming a familiar catalogue number guarantees an unchanged supplied form or test package.

Document the purchasing decision

Use a discrepancy log with a responsible person, requested evidence, due date and disposition. Distinguish an administrative correction from an unresolved identity or lot mismatch. If a critical link remains unexplained, keep the lot on hold rather than allowing a lower price or an attractive COA layout to substitute for the missing evidence.

This is a proposed buyer workflow, not a report of an audit performed by this website. Start a technical enquiry with the intended use and required documents, or review the site’s quality documentation scope. Catalogue listings remain research-oriented; they do not establish suitability for human administration or a destination-market authorisation.

Record the reason for acceptance beside each required evidence item. If commercial approval is conditional, state the condition and the person responsible for closing it. The receiving team should be able to distinguish a fully accepted supplier file from an order awaiting analytical documents.

Scope: B2B research-material procurement. This article provides no dosing, treatment or human-use instructions. Product-specific acceptance requires the signed specification and actual lot records.

Request a specification and document review with the material identifier, supplied form, quantity basis and destination. Availability and test scope require project confirmation.